Thematic Review Series: Bile Acids

Bile acids: regulation of apoptosis by ursodeoxycholic acid

Joana D. Amaral,* Ricardo J. S. Viana,* Rita M. Ramalho,* Clifford J. Steer,† and Cecília M. P. Rodrigues1,*

Research Institute for Medicines and Pharmaceutical Sciences,* Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; and Departments of Medicine,1 and Genetics, Cell Biology, and Development, University of Minnesota Medical School, Minneapolis, MN

Abstract  Bile acids are a group of molecular species of acidic steroids with peculiar physical-chemical and biological characteristics. At high concentrations they become toxic to mammalian cells, and their presence is pertinent in the pathogenesis of several liver diseases and colon cancer. Bile acid cytotoxicity has been related to membrane damage, but also to nondetergent effects, such as oxidative stress and apoptosis. Strikingly, hydrophilic ursodeoxycholic acid (UDCA), and its taurine-conjugated form (TUDCA), show profound cytoprotective properties. Indeed, these molecules have been described as potent inhibitors of classic pathways of apoptosis, although their precise mode of action remains to be clarified. UDCA, originally used for cholesterol gallstone dissolution, is currently considered the first choice therapy for several forms of cholestatic syndromes. However, the beneficial effects of both UDCA and TUDCA have been tested in other experimental pathological conditions with deregulated levels of apoptosis, including neurological disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Here, we review the role of bile acids in modulating the apoptosis process, emphasizing the anti-apoptotic effects of UDCA and TUDCA, as well as their potential use as novel and alternate therapeutic agents for the treatment of apoptosis-related diseases.—Amaral, J. D., R. J. S. Viana, R. M. Ramalho, C. J. Steer, and C. M. P. Rodrigues. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. 2009. 50: 1721–1734.

Supplementary key words  Bcl-2 family • cell death • liver • neuroprotection • nuclear steroid receptors

Bile acids, the major constituents of bile, are produced in the liver and secreted into the intestine, where they play crucial biological roles, such as solubilization of lipids in the intestinal lumen, among many others. Interest in bile acids has grown markedly over the last decades since discovering the role of these acidic steroids in several important physiological phenomena, including liver and intestinal pathology and pharmacology. Certain bile acids are cytotoxic molecules implicated in increased cell proliferation and cancer development in the intestinal tract (1) and/or cell death by necrosis and apoptosis. In fact, apoptosis has been described as a key event during hepatobiliary diseases (2). Curiously, not all bile acids are toxic, and previous studies suggest that this may be related to minor changes in their chemical structure (3). In this regard, accumulation of hydrophobic bile acids within the hepatocyte induces cell death of liver cells during cholestasis, while hydrophilic bile acids may be cytoprotective (Fig. 1). Ursodeoxycholic acid (UDCA), for instance, is an endogenous hydrophilic bile acid in clinical use for the treatment of certain liver diseases. There is now strong evidence that the cytoprotective effects of this molecule result, in part, from its ability to reduce the apoptotic threshold in several cell types through modulation of classical mitochondrial pathways. Interestingly, the use of UDCA as an agent to treat nonliver diseases associated with increased levels of apoptosis, such as neurodegenerative disorders, is...
CYP7A1 have been described and include the small heterodimer partner (SHP)/liver receptor homolog-1 (LRH-1) in liver and the fibroblast growth factor intestine 19 (FGF19)/tyrosine kinase FGF receptor 4 (FGFR4) in intestine. Nevertheless, other mechanisms independent of FXR signaling have also been identified (8, 9).

In the liver, activation of FXR by hydrophobic bile acids induces the expression of the SHP transcriptional repressor (10). SHP, in turn, negatively interacts with other transcription factors, such as LRH-1, which has been shown to enhance cyp7a1 and cyp8b1 basal transcription (11). Because SHP binds efficiently to LRH-1 and inhibits its transcriptional activity, it was proposed that this interaction induces cyp7a1 and cyp8b1 repression (12, 13). Most notably, recent studies using mice models of LRH-1 tissue specific deficiency have changed the classic panorama of bile acid synthesis feedback inhibition (14, 15). Surprisingly, LRH-1 deficiency in mouse liver had no significant effect on either basal cyp7a1 expression or its repression by FXR. This was in agreement with previously published data showing that SHP gene knockout did not prevent bile acid inhibition of cyp7a1 mRNA expression in mice (16, 17), thereby suggesting an additional regulatory pathway. In contrast, cyp8b1 expression was significantly reduced and accompanied by predicted changes in the bile acid pool. LRH-1 also appears to induce the expression of other genes, including shp in liver and both shp and fgf15 in the ileum, as revealed by LRH1 knockout in mouse liver and intestine, respectively (15).

Most studies on the feedback mechanisms involved in bile acid homeostasis have focused on liver with little attention paid to the intestine. Nevertheless, several reports reveal that the intestine also plays an active role in bile-acid-mediated suppression of bile acid synthesis in liver. For example, FXR induces FGF15, an ortholog of human FGF19, in mouse intestine where expression is inversely correlated to that of cyp7a1 mRNA levels in mouse liver (18). FGF19 was reported to activate FGFR4 signaling, thus inhibiting CYP7A1 mRNA expression levels in human hepatocytes (19). Moreover, specific liver and intestine FXR knockout confirmed that intestinal FXR is required for bile acid inhibition of CYP7A1 in liver (20). In fact, unlike inhibiting apical bile acid transport, blocking basolateral bile acid transport resulted in reduced hepatic bile acid synthesis with increased FGF15 ileal expression (21). FGF15 may function as an interface signal between the intestine and the liver, affecting CYP7A1 expression independently by modulating the activity of bile acids or other molecules that signal from intestine to liver. However, this model is hard to reconcile with the finding that induction of FGF15 expression in the ileum of bile duct ligated mice correlates with a significant reduction in CYP7A1 mRNA levels in liver. Further, ileal-derived FGF15 might function as a signaling hormone acting on the liver via FGFR4 to repress CYP7A1 expression and bile acid synthesis (18). In addition, the FGF15/FGFR4 pathway synergizes with SHP to regulate bile acid synthesis. While the mechanism responsible for cooperation between the FGF15/FGFR4 and SHP pathways remains to be clarified, recent studies raise
the possibility that they are linked by a c-Jun NH₂-terminal kinase (JNK)-dependent pathway (18).

In the last few years, with the discovery of FXR, and more recently of TGR5, a bile acid membrane receptor (22, 23), the role of bile acids as signaling molecules with important paracrine and endocrine functions has become more evident (24). Apart from the regulation of their own synthesis and transport, bile acids are involved in triggering the adaptive response to several insults to the liver (25). Furthermore, their role in the control of general energy-related metabolism, and more precisely in hepatic glucose handling, has been reported (26). Finally, bile acids display central roles in modulating liver cell death pathways as well as survival transduction pathways (Fig. 1).

KEY MECHANISMS OF APOPTOSIS

Apoptotic cell death is a highly regulated mechanism that can be viewed as a program of cell suicide vital for a wide variety of biological processes. The irony of the apoptosis process is that death is the basis for establishing life. In fact, apoptosis is an integral part of normal embryonic development and tissue homeostasis during adulthood. Sculpture of fingers and toes is a classic example of apoptosis, where cells between the digits must actually die to separate them. Apoptosis has also been documented as a prominent player in immune regulation and tissue homeostasis as well as in pathological and therapeutic settings. Defects in physiological pathways of apoptosis may occur, contributing to the development of numerous medical illnesses for which adequate therapy or prevention is lacking. In fact, excessive apoptosis can lead to T-cell depletion, neurodegenerative diseases, or hepato-cellular degeneration, while impaired apoptosis contributes to oncogenesis, autoimmune diseases, and persistent infections (27). Thus, it is not surprising that apoptosis has become a topic of intensive research to identify molecular targets and propose effective therapies in the management of apoptosis-associated disorders.

Cells dying by apoptosis present a number of morphological changes that include chromatin condensation, cytoplasmic shrinkage, membrane blebbing, and the generation of small apoptotic vesicles containing intact cytoplasmic organelles as well as nuclear remnants (28). These apoptotic bodies are rapidly eliminated by resident phagocytic and neighboring cells, preventing the release of cellular components into the extracellular space and resulting inflammatory and immune response. Besides the morphological changes, apoptotic cells undergo a number of distinct biochemical events involving the loss of mitochondrial membrane potential, DNA fragmentation, and protein cleavage (29).

BIOCHEMICAL PATHWAYS OF APOPTOSIS

The apoptotic process may occur by several molecular pathways. The best characterized and most prominent, however, is the intrinsic pathway, involving mitochondria (30), and the extrinsic pathway, which is activated by death receptors at the cellular membrane (31). Although apparently independent, these two apoptotic pathways may interact through a finely orchestrated crosstalk involving key proteins that are common to both pathways.

Mitochondrial pathway

The mitochondrial pathway of apoptosis is triggered by intracellular stresses that converge on mitochondria, leading to membrane permeabilization, release of apoptogenic proteins, and disruption of the mitochondrial membrane potential. These changes culminate in activation of caspases and ultimately cell death (for a review, see Ref. 32). Mitochondrial membrane permeabilization may occur by the opening of the mitochondrial permeability transition pore or through the formation of specific release channels in the outer membrane, promoted by pro-apoptotic members of the Bcl-2 family. Bcl-2 family members regulate the mitochondrial pathway in both a positive and negative fashion (33). In unstressed cells, anti-apoptotic members (e.g., Bcl-2, Bcl-xL, and Bcl-w) are integral membrane proteins localized in the mitochondrial outer membrane. In contrast, pro-apoptotic members (e.g., Bax and Bak) are usually located in the cytosol as inert forms. Following induction of apoptosis, Bax and Bak undergo conformational changes, oligomerize, and translocate to mitochondria, where they directly or indirectly form specific pores for the release of apoptogenic factors, such as cytochrome c. Once in the cytosol, cytochrome c oligomerizes with Apaf-1, recruiting procaspase-9 to form the apoptosome. This results in cleavage and activation of caspase-9, which in turn cleaves and activates downstream caspases that function as effectors of the apoptotic process.

Death receptor pathway

The classical death receptor pathway of apoptosis is triggered by ligand-induced activation of death receptors at the cell surface, followed by recruitment and oligomerization of intracellular adaptor molecules (34). Death receptors are type 1 transmembrane proteins, belonging to the tumor necrosis factor (TNF) receptor superfamily (35), and include TNF receptor-1, CD95/Fas, TRAIL (TNF-related apoptosis inducing ligand) receptors 1 and 2, and death receptors 3 and 6. As an alternative, the extrinsic pathway can be activated by dependency receptors, which are believed to be connected to rapid caspase activation. In the absence of ligand, these receptors deliver a death signal through yet unidentified mediators, thus generating a state of cellular dependence from their ligands (36).

Caspase-8 is the dominant death receptor-activated initiator caspase. In type I cells, caspase-8 directly activates effector caspases perpetuating the apoptotic process (37). Importantly, in type II signaling cells, such as hepatocytes, progression of the apoptotic cascade depends entirely on its amplification by mitochondria (38). In this case, caspase-8 cleaves inactive cytoplasmic Bid. Once activated, cytoplasmic Bid induces conformational changes in pro-apoptotic Bax and Bak, which in turn transduce the death stimuli to mitochondria (39). This coordination
between both pathways reinforces the critical role of mitochondria during programmed cell death.

**Cell cycle and apoptosis**

Apoptosis and proliferation are intimately coupled. In fact, tissue homeostasis is dependent on the precise balance between cell proliferation and cell death; thus, it is not surprising that some cell cycle factors modulate both processes. In eukaryotic cells, the key trigger for the progression from one phase of the cell cycle to the next and, ultimately, cell cycle progression results from a complex series of interactions between cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CDKIs). Different cyclins act at distinct phases of the cell cycle by binding to and stimulating the activities of CDKs. Cyclin D1, for instance, specifically regulates the G1-to-S progression of the cell cycle. In addition to their CDK-binding activities, D-type cyclins possess CDK-independent properties and form physical associations with several transcription factors (41). Although the role of cyclins and CDKs in stimulating cell cycle progression and proliferation is indisputable, there is increasing evidence to suggest that these, as well as other cell cycle-related proteins, may also play critical roles in cell growth inhibition, senescence, and apoptosis (42). For example, it was initially shown that cyclin D1 mRNA levels were strongly increased during the death of neurons (43). However, the mechanisms by which cyclin D1 induces apoptosis are far from completely understood.

Additional regulatory controls that can initiate apoptosis include the E2F-1 transcription factor. As a member of the E2F family, it not only regulates the expression of many genes necessary for normal proliferation, in a cell-cycle-specific manner, but has also been implicated in inducing apoptosis (44). E2F-1 is typically bound to the unphosphorylated retinoblastoma protein (pRb). However, under certain stress conditions and during cell cycle, inactivation of pRb by phosphorylation releases E2F-1 to transactivate genes necessary for apoptosis. Curiously, some studies suggest that ectopic expression of cyclin D1 may cause apoptosis by phosphorylating pRb, resulting in deregulation of the pRb/E2F complex (45). In addition, activation of p53 is one of the mechanisms involved in E2F-1-induced apoptosis. In the absence of stress signals, p53 is kept in check to allow normal cell proliferation and/or maintenance of cell viability. The p53 protein is mainly regulated at the posttranslational level by Mdm-2, or in humans, Hdm-2, which has been shown to inhibit p53 activity by regulating its stability, cellular localization, and ability to activate transcription (46). Interestingly, E2F-1 stabilizes p53 by induction of alternate reading frame (ARF), which directly binds to Mdm-2 and prevents p53 proteasomal degradation.

The link between cell cycle and apoptosis has also been recognized in proteins such as c-Myc, Ras, and other cell cycle regulators, including p21 and p27. In fact, some of these proteins are targets for cleavage by caspases, underscoring the absence of cell cycle progression during apoptosis (47). A relationship between bile acids and cell proliferation also exists (48). Taken together, induction of apoptosis depends on the cellular environment where conflicting signals for cell proliferation and cell cycle arrest may result in cell death.

**Bile Acid Induction of Apoptosis**

The mechanisms by which bile acids induce apoptosis in hepatocytes are still not entirely known. It was thought that hydrophobic bile acids, such as glycochenodeoxycholic (GCDCA) and taurochenodeoxycholic acids, could induce cytotoxicity by acting as detergents on cell membranes. Nevertheless, serum bile acid levels in cholestatic patients are insufficient to produce a significant detergent effect; therefore, bile acid cytotoxicity appears to result from other processes. In fact, basic cellular mechanisms of hepatocyte injury might be primarily involved, ultimately causing cell death by either necrosis or apoptosis. There are several studies showing association between caspase activation, mitochondrial dysfunction, and cellular distribution of Bcl-2-related proteins in models of cholestasis and hepatocyte injury (49). Indeed, pathophysiological concentrations of bile acids induce apoptosis both by directly activating death receptors (50) and inducing oxidative damage and mitochondrial dysfunction (51, 52), a combination that strongly sensitizes cells to apoptosis (Fig. 1). In addition, the activation of death receptors invariably signals the mitochondrial pathway of apoptosis in hepatocytes. Thus, hydrophobic bile acids are unique among naturally occurring apoptotic agents due to their potential to induce apoptosis through both nonspecific detergent effects and receptor-mediated interactions.

Toxic bile acids have been shown to induce apoptosis in a Fas- and TRAIL-dependent manner (50, 55), involving recruitment of the Fas-associated death domain (FADD), activation of caspase-8 and Bid, as well as downstream effector caspases. Activation of death receptors by bile acids involves induction of their transport from the Golgi (54). Spontaneous receptor oligomerization then occurs at the cell membrane. As an example, lithocholic-acid-induced apoptosis in colon cancer cell lines proceeds through a mitochondrial/caspase-9-dependent pathway initiated by caspase-8 (55). Bile acids are also known to cause ligand-independent activation of Fas in hepatocytes, resulting in subsequent caspase-8 activation. The mechanism of Fas activation has been studied in hepatocytes and is thought to occur through generation of oxidative stress by dihydroxy bile acids followed by epidermal growth factor receptor-dependent Fas translocation and oligomerization (56, 57). Bile acid oxidative stress, which ultimately leads to Fas activation, can be generated through a multifactorial mechanism involving NADPH oxidase activation and interaction of bile acids with mitochondria to directly generate reactive oxygen species (ROS) (58). More recently, G-protein-coupled receptor TGR5 activation has also been implicated in Fas translocation and oligomerization (59), which is in agreement with previous results showing TGR5 activation by lithocholic and chenodeoxycholic acids (60). Alternatively, Fas activation by Fas ligand or other agonists may
also be increased; interestingly, this process is stimulated by p53. The transcription factor was shown to transiently increase Fas expression at the cell surface via transport from the Golgi complex and to induce Fas-FADD binding (61). In addition, p53 was implicated in cyclin kinase inhibitor-enhanced, bile-acid-induced apoptosis via Fas (62).

Novel findings in the field point to a critical role of caspase-6 in bile-acid-mediated apoptosis of human liver cell lines and primary rat hepatocytes (63). Caspase-6, generally considered an executioner caspase, has recently been identified as a potential activator of caspase-8 in models of bile-acid-induced apoptosis. This protease appears to be part of a feedback loop in bile-acid-induced apoptosis of hepatocytes, thereby enhancing the toxicity of pro-apoptotic bile acids. Curiously, caspase-6 activation is less important in apoptosis induced by other stimuli in the same cells. Finally, although mitochondrial cytochrome c release is FADD/caspase-8 dependent during hepatocyte apoptosis, pro-apoptotic bile acids, at concentrations similar to those found in cholestatic liver injury, are still capable of inducing apoptosis by the intrinsic pathway when death receptor activation is inhibited (63). Recently, apoptosis via the endoplasmic reticulum (ER) stress-mediated pathway was also found in GCDCA-induced apoptosis of liver cells, although to a lesser extent (64, 65). Treatment with the bile acid resulted in ER-related Ca$^{2+}$ release, increased calpain and caspase-12 activities, and induction of the ER stress biomarkers Bip and Chop mRNA expression levels. Therefore, inhibition of death receptor signaling alone is probably not sufficient to reduce hepatocyte apoptosis and consecutive bile-acid-induced liver damage in cholestatic diseases.

**BILE ACID INHIBITION OF APOPTOSIS**

**Cell survival signaling**

Although bile acids are inherently toxic compounds, they are also potent signaling agents that modulate intra-cellular molecular pathways (Fig. 1). Interestingly, these molecules are capable of inhibiting their own cytotoxicity by triggering survival signals (66). The so-called survival signaling pathways have evolved to protect cells from pathologic apoptosis and include nuclear factor κB (NF-κB), phosphatidylinositol 3-kinase (PI3K), and mitogen-activated protein kinase (MAPK) pathways (Fig. 2). Survival stimuli generally trigger intracellular signaling through activation of transmembrane receptors. The liver has the ability to limit apoptosis during cholestasis by triggering specific mechanisms. Although it has been shown that Bcl-2, Bcl-2, Bcl-X$_L$, and Bax are expressed in the liver, only cholangiocytes and not hepatocytes normally express anti-apoptotic Bcl-2. However, induction of cholestasis by bile duct ligation leads to Bcl-2 expression in hepatocytes, which may represent an adaptive phenomenon to protect hepatocytes. In addition, the activation of NF-κB and subsequent regulation of anti-apoptotic genes (67), as well as the cytoplasmic sequestration of p53 (68), are mechanisms triggered by the liver to inhibit or modulate apoptosis induced by toxic bile acids.

Several studies have linked bile-acid-induced extracellular-regulated kinase (ERK) signaling to a cytoprotective response against bile-acid-induced Fas receptor/caspase activations (56, 69, 70). In addition, JNK signaling may have both pro- and anti-apoptotic effects, including those that are downstream of the TNF-α receptor in hepatocytes (71). In this regard, the bile acid deoxycholic acid (DCA) activates both ERK and JNK pathways. While DCA-induced ERK1/2 and JNK2 signaling appears to be mainly cytoprotective, DCA-induced JNK1 is cytotoxic. Triggering of the ERK cascade by DCA results in increased DNA binding of CCAAT enhancer binding protein B (C/EBPβ) and cyclic AMP-response element binding protein (CREB), two putative cytoprotective transcription factors. Paradoxically, it has been determined that DCA-induced JNK1/2 activation is dependent on Fas signaling, which implies that bile-acid-induced activation of Fas can generate opposing signals. On the one hand, it activates caspase and JNK1 activation, resulting in cell death; on the other hand, it induces JNK2 leading to protection (72). Other studies have demonstrated that some bile acids activate PI3K-dependent survival pathways to prevent their otherwise inherent toxicity (73–75) or protect against more hydrophobic bile acids species (66, 76). In this respect, bile acids appear to dance with both death receptors and cell survival cascades; the balance likely lies within the strength and fidelity of the dancing partner (77).

**UDCA modulation of apoptosis**

In contrast to the toxic effects of hydrophobic bile acids, UDCA is a hydrophilic bile acid widely used as a therapeutic drug for patients with cholestatic liver diseases (78, 79). At present, it is the only drug approved by the United States Food and Drug Administration for the treatment of primary biliary cirrhosis. Despite its clinical efficacy, the precise mechanism by which UDCA improves liver function is still not entirely understood. It is now well established that inhibition of liver cell apoptosis is one of the main routes for the protective effect of UDCA, along with protection of cholangiocytes against cytotoxicity of hydrophobic bile acids and stimulation of impaired biliary secretion (80). Most likely, UDCA protective function results from a coordinated process involving several effects, depending on the type and stage of the disease.

The anti-apoptotic effects of UDCA have been demonstrated both in rat liver (81, 82) and isolated human hepatocytes (83). While toxic bile acids fed to rats induce apoptosis in the liver, UDCA inhibits this effect by preventing formation of ROS and translocation of the pro-apoptotic protein Bax from the cytosol to the mitochondria. More importantly, these effects were also observed in non-hepatic cells, indicating that UDCA acts as a pleiotropic agent playing a unique role in modulating the classic mitochondrial pathway of apoptosis in different cell types (84). UDCA and its amidated conjugates, tauroursodeoxycholic acid (TUDCA) and glycoursodeoxycholic acid, were shown...
An important role in controlling gene expression. More recently, nuclear translocation of UDCA mediated by nuclear steroid receptors (NSRs) was shown to be essential for its anti-apoptotic properties (92) (Fig. 3). Once in the nucleus, UDCA might regulate gene expression by interacting directly with chromatin or alternatively through interaction with nuclear proteins, such as transcription factors. These findings have opened new avenues for UDCA protection from apoptosis. Microarray studies revealed that UDCA per se modulates the expression of at least 96 genes in primary rat hepatocytes, most of them involved in apoptosis and cell cycle regulation (93). UDCA was shown to reduce transcriptional activation and expression of cyclin D1 in hepatocytes incubated with DCA, which appears to contribute to the anti-apoptotic effects of the hydrophilic bile acid (94). On the other hand, TUDCA also appears to modulate apoptosis induced by toxic bile acids through inhibition of the human transcription factor activating protein-1 (AP-1) (95). Importantly, AP-1 is a dimer consisting of proteins belonging to Jun, Fos, ATF, or MAF families, which is involved in the regulation of cell proliferation, transformation, and death (96).

UDCA inhibition of apoptosis also involves modulation of other transcription factors, such as E2F-1 and p53,
Ursodeoxycholic acid anti-apoptotic function

Activation of survival pathways may represent important additional mechanisms by which UDCA inhibits cell death. For example, UDCA can stimulate the MAPK and the PI3K signaling pathways. In fact, it has been demonstrated that the p38/ERK/MAPK and PI3K pathways are involved in protection of TUDCA against GCDCA-induced apoptosis in rat hepatocytes (66). TUDCA also significantly inhibited each of the amyloid β (Aβ)-induced apoptotic events in rat neuronal cells, in part, through activation of the PI3K pathway (105). In addition, it protected cardiomyocytes in culture against reperfusion injury in a PI3K/Akt-dependent pathway (106).

It is interesting to note that UDCA may also be cytoprotective through mechanisms other than inhibition of apoptosis. In fact, UDCA has the ability to suppress the NF-κB pathway and subsequent cytokine expression via activation of the glucocorticoid receptor (GR), thereby playing an important anti-inflammatory role in the liver (107).

**Fig. 3.** Proposed mechanisms of UDCA and TUDCA inhibition of apoptosis. UDCA negatively modulates the mitochondrial pathway by inhibiting Bax translocation, ROS formation, cytochrome c release, and caspase-3 activation. UDCA can also interfere with the death receptor pathway, inhibiting caspase-3 activation. Moreover, TUDCA inhibits apoptosis associated with ER stress by modulating intracellular calcium levels and inhibiting calpain and caspase-12 activation. Importantly, UDCA interacts with NSR, leading to NSR/hsp90 dissociation and nuclear translocation of the UDCA/NSR complex. Once in the nucleus, UDCA modulates the E2F-1/p53/Bax pathway, thus preventing apoptosis. Finally, UDCA downregulates cyclin D1 and Apaf-1, further inhibiting the mitochondrial apoptotic cascade. See text for more complete description. Cyt c, cytochrome c; Hsp90, heat shock protein 90.
Crosstalk between bile acids and NSRs

During the past several years, it has become evident that the NSR family of transcription factors regulates apoptosis in different cell systems. Curiously, NSRs play a heterogeneous function in apoptosis, which is affected by tissue-specific parameters, such as alternative initiation sites within nuclear receptor genes as well as the varying effects of comodulators. However, the mechanism by which NSR can differentially affect the expression of the same subset of genes for different cells is still a matter of debate. Bile acids, as cholesterol-derived molecules, share chemical and structural similarities to steroid hormones and can potentially bind and modulate NSR activation. In fact, they are now considered cognate ligands of certain nuclear receptors originally classified as orphan nuclear receptors.

The link between UDCA and the GR was primarily correlated with anti-inflammatory properties of the bile acid. Interestingly, UDCA has also been described as a regulator of the immune response, and its immunomodulatory effects in cholestatic liver diseases show similarities with glucocorticoid (GC)-mediated immunomodulation. Several attempts have been made to identify GC-induced genes by using advent microarray technologies. Nevertheless, many of the target genes whose transactivation or transrepression by GR somehow modulates apoptosis remain uncertain. Although GR acts primarily as a transcription factor, it also exhibits distinct nongenomic effects. As an example, GR has been shown to be located within mitochondria in some cell types, which may be a crucial step in triggering apoptosis (108). The upregulation of GR-mediated gene transcription appears to enhance apoptosis of myeloma cells, osteoblasts, lymphoid cells, and neuronal cells. Importantly, GR activation has been correlated with excessive cell death pathological conditions, such as Alzheimer’s and Parkinson’s diseases (109, 110). At odds with its pro-apoptotic effects in certain cell types, GR also mediates prosurvival signals in others. Strikingly, profound protective effects against apoptosis have been continuously attributed to GR in several liver-derived cells (111, 112). Rat liver regeneration is also thought to involve elevated expression of GR (113). Interestingly, GR was also found to physically interact with the tumor suppressor p53 and its dual role in inducing apoptosis or cell cycle arrest. The functional interactions between GR and p53 in different physiological conditions may significantly alter the effects of each transcription factor (114).

Studies from our lab have shown that GR is required for UDCA anti-apoptotic function. For example, the endogenous silencing of GR abolished the protective effect of UDCA against transforming growth factor β1 (TGF-β1)-induced apoptosis in primary rat hepatocytes (115). During TGF-β1-induced apoptosis, significant degradation of GR occurs in liver cells. However, pretreatment of cells with UDCA not only markedly upregulated GR but also resulted in increased receptor nuclear translocation, when compared with TGF-β1 alone. In addition, the transcription factor E2F-1 was found to be a potent target for UDCA-induced GR activation. In fact, changes in E2F-1 protein levels induced by TGF-β1 were no longer prevented by UDCA after transfection of hepatocytes with small interfering RNA to GR. Furthermore, the subsequent increase in levels of the p53 repressor Mdm-2 and the decrease of p53 induced by UDCA were abrogated with GR silencing, thus supporting the notion of E2F-1 modulation (Fig. 3). However, the precise link between NSR and UDCA-regulated E2F-1, Mdm-2, and p53 remains to be determined. Other authors have also suggested that GR interferes with the expression of mitogenic factors, such as cyclins, CDKs, and E2F-1 (116).

More recently, there have been additional insights on how NSRs are involved in UDCA as an anti-apoptotic agent. Indeed, we demonstrated that UDCA promotes the dissociation between GR and its molecular chaperone, hsp90, thus inducing subsequent GR translocation into the nucleus of hepatocytes (92). However, when the C-terminal region of GR was deleted, UDCA no longer induced GR/hsp90 dissociation or GR nuclear translocation nor protected against apoptosis, indicating that GR ligand binding domain (LBD) is at least one target domain required for the anti-apoptotic function of UDCA. By using a fluorescently labeled UDCA molecule, we clearly demonstrated that UDCA reaches the nucleus of primary rat hepatocytes in a GR-dependent mechanism. Nuclear translocation of NSR by bile acids may not always result in transactivation or transrepression of NSR. In fact, bile acids might only require NSR to reach the nucleus, where they themselves regulate genes through modulation of other transcription factors. Indeed, although GCs are well-known inhibitors of apoptotic cell death, we showed that the protective role of UDCA does not require GR transactivation in liver cells. UDCA increases the activation of GC response elements in hepatocytes that overexpress GR but does not protect against TGF-β1-induced apoptosis by further increasing GR transactivation. Therefore, it is conceivable that UDCA requires NSR for translocation to the cell nucleus as part of a ligand-receptor complex, using a mechanism similar to that of steroid hormones (Fig. 3).

Interestingly, other studies have demonstrated that UDCA interacts with GR in the absence of specific ligands, as a novel and selective GR modifier (117). In addition, it was reported that UDCA promotes DNA binding of GR through interaction with its LBD, but without eliciting GR transactivation (107). Only under certain conditions may UDCA enhance GR-responsive gene expression. For example, in the presence of dexamethasone, UDCA increases GR-induced tyrosine aminotransferase, a hepatocyte-specific marker of GR (118). Although there is no structural evidence for the direct binding of UDCA to GR, it is thought that UDCA acts at a region of the LBD distinct from that of dexamethasone. UDCA then possibly modulates GR structure into a unique conformation that can translocate into the nucleus and bind DNA, but no longer interacts with coactivators to elicit transcriptional activation. These data may, in part, explain the anti-inflammatory properties of UDCA. In fact, UDCA pretreatment was shown to suppress DNA binding activity of AP-1 and repressed NF-κB-dependent transcription via interaction of GR with NF-κB. It is generally felt that transrepression of such
transcription factors is the primary mechanism by which GCs mediate their anti-inflammatory activity. Moreover, different ligands induce various conformations of NSRs leading to unique regulatory properties of the receptors. It is therefore possible that UDCA may regulate several apoptosis-related genes by functionally modulating GR. Other mechanisms of GR activation by UDCA might be membrane related and involve an unidentified secondary signal that activates other signal transduction pathways. Although GRs share similar ligands and interact with the same genes as the mineralocorticoid receptor (MR), they may also form heteromeric complexes in which MR represses GR function (119). Thus, although there is no evidence that MR and UDCA interact directly, it is conceivable that UDCA-mediated modulation of GR may also affect MR.

The function of MR during apoptosis is thought to be primarily protective in nature. In the brain, stress-induced GR activation leads to an arrest of neurogenesis and increased apoptosis, which in turn is inhibited by MR activation. In addition, MR increases neuronal survival by decreasing p53 levels as well as the ratio of pro-apoptotic to anti-apoptotic members of the Bcl-2 family (120). This is thought to result from repression of GR by MR. The anti-apoptotic action of MR has been extensively described in neuronal cells, but less is known about its role during hepatocyte apoptosis. Interestingly, our results have suggested a relevant mechanistic function for MR during hepatocyte apoptosis. We demonstrated that much like GR, MR contributes to the protective effect of UDCA against the E2F-1/Mdm-2/p53 apoptotic pathway induced by TGF-β1 in primary rat hepatocytes (115). In addition, E2F-1, Mdm-2, and p53 were also found to be potent targets for UDCA-induced MR activation in liver cells. However, in the presence of Aβ peptide, TUDCA appears to differentially modulate MR and GR nuclear translocation in rat cortical neurons (121). In fact, TUDCA preferentially interacted with MR LBD, thus promoting MR dissociation from its cytosolic chaperones and translocation to the nucleus. It is possible that specific comodulators in neuronal cells may somehow induce TUDCA-mediated MR nuclear translocation, while reducing GR nuclear traffic. Surprisingly, and in contrast to hepatocytes, pretreatment of rat pheochromocytoma (PC12) cells with TUDCA significantly modulated Aβ-induced changes in MR and GR transactivation. In fact, the transcriptional activity of MR was increased while GR transactivation was reduced by TUDCA. This differential modulation of GR and MR in hepatocytes and PC12 cells suggests that additional pathways exist for the anti-apoptotic function of UDCA and TUDCA involving NSR as key factors. Whether UDCA and TUDCA may also regulate apoptosis through differential mechanisms of action is unclear.

UDCA has also been shown to regulate activity of other nuclear receptors. In fact, UDCA is a relatively strong pregnane X receptor (PXR) agonist and a weaker FXR agonist. Although UDCA does not itself bind FXR, it does inhibit receptor activation by more hydrophobic bile acid species (122). Moreover, during liver regeneration, increased levels of UDCA were shown to inhibit bile acid-FXR mediated repression of several genes (123). Other studies have shown that UDCA activates PXR to induce CYP3A4 (124). PXR is transcriptionally active in stellate cells by inhibiting transformation and proliferation. It is possible then that the antifibrotic effects of UDCA are also mediated via PXR.

**BILE ACIDS AS TREATMENT OF EXPERIMENTAL NEURODEGENERATIVE DISORDERS**

**Inhibition of neuronal apoptosis by bile acids**

Neurodegeneration corresponds to any pathological condition primarily affecting neurons (125). Neurodegenerative diseases are associated with a number of insults that may trigger the apoptotic process, including misfolded proteins, reactive oxygen and nitrogen species, mitochondrial complex inhibition, calcium imbalance, excitotoxicity, trophic factor withdrawal, and death receptor activation (126).

The therapeutic role of UDCA has been established in the treatment of certain liver diseases. Importantly, UDCA has the ability to modulate apoptosis at several levels, suggesting a common mechanism for cell survival that is independent of cell type (82). Thus, the use of UDCA for nonliver diseases associated with increased levels of apoptosis, specifically neurological disorders, is now an active area of study. Interestingly, after conjugation with taurine, UDCA administrated in high doses can be delivered to other tissues, including the brain (127). TUDCA inhibits apoptosis induced by several stimuli in isolated neuronal cells (105, 128).

The protective role of TUDCA has been extended to several mouse models of neurological disorders, including Huntington’s disease. In fact, TUDCA markedly reduced the mitochondrial perturbations associated with apoptosis induction in cultured neuronal cells incubated with 3-nitropropionic acid (128). Consistently, the systemic administration of TUDCA in the 3-nitropropionic acid rat model of Huntington’s disease was shown to reduce the associated morphologic striatal lesions (127). Moreover, behavioral studies correlated with histopathological findings, since the neuroprotection resulted in almost prevention of hyperactive behavior. Initial studies were extended to the R6/2 transgenic mouse model of Huntington’s disease, where it was demonstrated that administration of TUDCA significantly reduced striatal neurodegeneration and ameliorated locomotor and sensorimotor deficits (129).

Interestingly, it was also shown that TUDCA can improve the survival and function of nigral transplants in a rat model of Parkinson’s disease (130). In fact, TUDCA significantly reduced apoptosis in ventral mesencephalic tissue cultures and within the transplants, suggesting that the bile acid exerts beneficial effects on dopamine neuron survival mainly through neuronal death inhibition. In addition, TUDCA was shown to partially rescue a Parkinson’s disease model of *Caenorhabditis elegans* from mitochondrial dysfunction (131).
The anti-apoptotic role of TUDCA was extended to acute conditions, particularly to a rat model of transient focal cerebral ischemia (132). Importantly, it was demonstrated that intravenous administration of TUDCA reduced infarct volume by ~50%, modulated the levels of apoptosis, and inhibited the neurobehavioral impairment. In addition, TUDCA was capable of reducing the degree of brain injury and improving neurologic performance in a collagenase-induced hemorrhagic model of stroke by preserving mitochondrial membrane stability and inhibiting caspase activation (133).

Impressively, it has been recently shown that TUDCA preserves photoreceptor structure and function in the rd10 retinitis pigmentosa mouse model through postnatal day 30 (134). TUDCA was able to preserve rods and cones through postnatal day 30, the stage at which photoreceptor cell loss peaks. Thus, these experiments tested the efficacy of TUDCA at a critical stage of degeneration in retinitis pigmentosa. In addition, intraperitoneal injections of TUDCA were neuroprotective in a murine model of spinal cord injury (135). In fact, TUDCA reduced the number of necrotic and apoptotic cells by mitochondria stabilization, inducing a better functional outcome after spinal cord injury. Interestingly, pretreatment with TUDCA also significantly reduced glutamate-induced apoptosis of rat cortical neurons. TUDCA was capable of modulating glutamate-induced caspase activation and cytochrome c release, reducing the apoptotic threshold (136).

Prompted by these results, the anti-apoptotic role of TUDCA has recently been investigated in experimental models of Alzheimer’s disease. Alzheimer’s disease is the most common age-related neurodegenerative disorder (137). Amyloid plaques, extracellular deposits of mainly 40–42 Ab peptides, and neurofibrillary tangles, intraneuronal aggregates comprised primarily of hyperphosphorylated insoluble tau, are common brain lesions in Alzheimer’s disease. These aggregates are now strongly implicated in the onset and/or progression of Alzheimer’s disease, inducing several neurodegenerative changes, such as neuronal apoptotic death. Initial studies using primary rat neurons and astrocytes incubated with Ab showed increased levels of apoptosis, which was prevented by TUDCA and UDCA (138). The anti-apoptotic effects of TUDCA were further confirmed in PC12 neuronal cells incubated with Ab (139). Similar results were seen in in vitro models of familial Alzheimer’s disease consisting of mouse neuroblastoma cells expressing APP with the Swedish mutation, or double-mutated human APP and PS1 (140), and in primary cortical neurons incubated with fibrillar Ab1-42 (141).

Due to their potential role in Ab-induced toxicity, mitochondria were isolated and coincubated with TUDCA to assess its protective effect against apoptosis. In fact, UDCA, and more efficiently TUDCA, inhibited Ab-induced mitochondrial membrane permeabilization and consequent cytochrome c release in isolated neuronal mitochondria (138). Moreover, using electron paramagnetic resonance spectroscopy analysis, TUDCA prevented Ab-driven modifications in mitochondrial membrane redox status, lipid polarity, and protein order (142), in addition to decreasing Bax translocation (105). Similar results were obtained in primary human cerebral endothelial cells incubated with the vasculotropic E2F QAb mutant that is associated with hereditary cerebral hemorrhage in amyloidosis Dutch type (143). Interestingly, TUDCA was not capable of modulating the secondary structure and the fibrillogenic propensities of Ab, suggesting dissociation between the capacity to induce apoptosis and the mechanisms of aggregation and fibrilization.

It was also shown that, in PC12 neuronal cells, TUDCA interferes with upstream targets of the mitochondria, including the E2F-1/p53/Bax apoptotic pathway (139). The role of p53 in mediating the effects of TUDCA was further confirmed using in vitro models of familial Alzheimer’s disease (140). It is still not clear, however, how UDCA and TUDCA interfere with p53 expression and activation. It was demonstrated that UDCA reduced p53 transcriptional and DNA binding activities in hepatocytes undergoing p53-induced apoptosis by favoring its interaction with Mdm-2 (98). Thus, it is tempting to speculate that a similar effect would occur in neurons exposed to Ab.

TUDCA was also shown to mitigate the toxic downstream effects of Ab. In primary rat cortical neurons incubated with fibrillar Ab1-42, TUDCA inhibited the levels of apoptosis and caspase-3 activation and abrogated the caspase-3-cleavage of tau into a toxic species (141). Cleavage of tau by caspase-3 at Asp421 in the C-terminal region is detected in primary cortical neurons, transgenic mice, and brains affected by Alzheimer’s disease, promoting tau assembly (141, 144). Thus, by interfering with apoptotic pathways, both at the mitochondrial and transcriptional levels, TUDCA not only increased the survival of neurons but also prevented downstream abnormal conformations of tau. Finally, it is tempting to speculate that TUDCA may also modulate neuronal apoptosis by interfering with ER stress. Given the growing evidence supporting the implication of this mechanism in Alzheimer’s disease pathology, it would be of much interest to evaluate the chaperone capacity of TUDCA in Alzheimer’s disease models. Importantly, it was recently demonstrated that TUDCA administration to a transgenic mouse model of familial amyloidotic polyneuropathy significantly reduced transthyretin (TTR) toxic aggregates and decreased apoptotic and oxidative biomarkers usually associated with TTR deposition (145). These studies suggested that TUDCA modulated TTR aggregation by interfering with cellular responses, including ER stress.

**CONCLUSIONS**

In health, bile acids are essential for emulsifying lipids in the intestinal lumen, and their synthesis and transport drive bile formation and provide the major degradation pathway for cholesterol. Despite the beneficial effects, bile acids are always amphipatic molecules with inherent toxicity. With the realization that bile acids induce apoptosis, it was subsequently demonstrated that UDCA, the current and primary treatment of cholestasis, was a potent inhibitor of apoptosis by interrupting classic pathways of apoptosis. These studies provided a new framework to further...
understand and exploit the potential of this therapeutic agent. During the last decade, great progress has been made in characterizing the biochemical and molecular mechanisms underlying UDCA and its effects on cell survival. Most notably, it was protective from a long-list of apoptosis-inducing agents, and the effect was independent of cell type. In addition, given its clinical safety, UDCA and/or its conjugate derivatives may be potentially powerful therapeutic tools in several injuries associated with greater susceptibility to apoptotic cell death. For instance, UDCA is readily water soluble, can be administrated orally or intravenously, and is associated with minimal toxicity. Nevertheless, its clinical application to human diseases outside of liver has yet to be vigorously tested.

Importantly, apoptosis plays a role in many pathological conditions, affecting a wide range of tissues, including liver, kidney, central nervous system, and heart, among others. As such, the field continues to be enormously active at both the basic science and clinical levels. The future will certainly focus on documenting new associations between apoptosis and disease and developing more effective therapeutic strategies based on modulation of the apoptotic process.

The authors thank all members of the laboratory for critical reading of the manuscript.

REFERENCES


